Oxaliplatin-induced peripheral neuropathy with hepatic arterial versus intravenous infusion in metastatic colorectal cancer

被引:1
|
作者
Valery, Marine [1 ]
Tanguy, Marie-Laure [2 ,3 ]
Gelli, Maximiliano [4 ]
Smolenschi, Cristina [1 ,5 ]
Hollebecque, Antoine [1 ,5 ]
Boileve, Alice [1 ,6 ]
de Sevilla, Elena Fernandez [4 ]
Tselikas, Lambros [7 ]
Bonnet, Baptiste [7 ]
Goere, Diane [8 ]
Taieb, Julien [9 ]
Boige, Valerie [1 ]
Ducreux, Michel [1 ,6 ]
Malka, David [6 ,10 ]
机构
[1] Univ Paris Saclay, Dept Med Oncol, Gustave Roussy, F-94805 Villejuif, France
[2] Univ Paris Saclay, Serv Biostat & Epidemiol, Gustave Roussy, F-94805 Villejuif, France
[3] Univ Paris Saclay, Equipe Labellisee Ligue Contre Le Canc, INSERM, Oncostat U1018, Villejuif, France
[4] Univ Paris Saclay, Dept Chirurg Oncol, Gustave Roussy, F-94805 Villejuif, France
[5] Univ Paris Saclay, Dept Innovat Therapeut, Gustave Roussy, F-94805 Villejuif, France
[6] Univ Paris Saclay, INSERM, Unite Dynam Cellules Tumorales, Gustave Roussy, F-94805 Villejuif, France
[7] Univ Paris Saclay, Dept Imagerie Med & Radiol Intervent, Gustave Roussy, F-94805 Villejuif, France
[8] Hop Univ St Louis, Serv Chirurg Viscerale Cancerol & Endocrinienne, Paris, France
[9] Hop Europeen Georges Pompidou, Serv Oncol Digest, Paris, France
[10] Inst Mutualiste Montsouris, Dept Oncol Med, 42 Blvd Jourdan, F-75014 Paris, France
关键词
Neuropathy; Oxaliplatin; Hepatic arterial infusion chemotherapy; Metastatic colorectal cancer; QUALITY-OF-LIFE; III COLON-CANCER; LIVER METASTASES; COMBINATION CHEMOTHERAPY; REDUCED GLUTATHIONE; DOUBLE-BLIND; OPEN-LABEL; PHASE-II; CETUXIMAB; TRIAL;
D O I
10.1007/s00520-024-08807-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundOxaliplatin, a major drug in metastatic colorectal cancer (mCRC), is responsible for cumulative, dose-limiting peripheral neuropathy (PN). Whether the hepatic arterial infusion (HAI) route can limit oxaliplatin-induced PN in comparison with the intravenous (IV) route has not been specifically explored so far.MethodsWe compared the frequency and severity of PN in oxaliplatin-naive patients with mCRC included in trials that evaluated treatment with oxaliplatin administered either by HAI (ACCORD 04, CHOICE, OSCAR, and PACHA-01 trials) or by IV route (FFCD 2000-05 trial). We retrieved anonymized, prospectively collected data from trial databases for the ACCORD 04, CHOICE, and FFCD 2000-05 trials and through a review of Gustave Roussy patients' electronic medical records for PACHA-01 and OSCAR trials.The primary endpoint was the incidence of clinically significant PN (grades 2 to 4) according to the cumulative dose of oxaliplatin received. Secondary endpoints were time to onset of neuropathy as a function of the cumulative dose of oxaliplatin, discontinuation of oxaliplatin for neurotoxicity, and safety.MethodsWe compared the frequency and severity of PN in oxaliplatin-naive patients with mCRC included in trials that evaluated treatment with oxaliplatin administered either by HAI (ACCORD 04, CHOICE, OSCAR, and PACHA-01 trials) or by IV route (FFCD 2000-05 trial). We retrieved anonymized, prospectively collected data from trial databases for the ACCORD 04, CHOICE, and FFCD 2000-05 trials and through a review of Gustave Roussy patients' electronic medical records for PACHA-01 and OSCAR trials.The primary endpoint was the incidence of clinically significant PN (grades 2 to 4) according to the cumulative dose of oxaliplatin received. Secondary endpoints were time to onset of neuropathy as a function of the cumulative dose of oxaliplatin, discontinuation of oxaliplatin for neurotoxicity, and safety.ResultsA total of 363 patients were included (IV, 300; HAI, 63). In total, 180 patients in the IV group (60%) and 30 patients in the HAI group (48%) developed clinically significant PN, with no significant difference between the two groups (p = 0.23). No difference was shown in the time to onset of PN either (p = 0.23).ConclusionThe administration of oxaliplatin HAI rather than IV in the treatment of mCRC does not reduce the incidence, precocity, and severity of PN.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] Oxaliplatin-induced peripheral neuropathy’s effects on health-related quality of life of colorectal cancer survivors
    Cindy Tofthagen
    Kristine A. Donovan
    Mary Ann Morgan
    David Shibata
    Yating Yeh
    Supportive Care in Cancer, 2013, 21 : 3307 - 3313
  • [42] Oral glutamine is effective for preventing oxaliplatin-induced neuropathy in colorectal cancer patients
    Wang, Wei-Shu
    Lin, Jen-Kou
    Lin, Tzu-Chen
    Chen, Wei-Shone
    Jiang, Jeng-Kae
    Wang, Huann-Sheng
    Chiou, Tzeon-Jye
    Liu, Jin-Hwang
    Yen, Chueh-Chuan
    Chen, Po-Min
    ONCOLOGIST, 2007, 12 (03): : 312 - 319
  • [43] Oxaliplatin-induced peripheral neuropathy's effects on health-related quality of life of colorectal cancer survivors
    Tofthagen, Cindy
    Donovan, Kristine A.
    Morgan, Mary Ann
    Shibata, David
    Yeh, Yating
    SUPPORTIVE CARE IN CANCER, 2013, 21 (12) : 3307 - 3313
  • [44] A systematic review on chronic oxaliplatin-induced peripheral neuropathy and the relation with oxaliplatin administration
    A. J. M. Beijers
    F. Mols
    G. Vreugdenhil
    Supportive Care in Cancer, 2014, 22 : 1999 - 2007
  • [45] Hepatic arterial infusion of chemotherapy for metastatic colorectal cancer - Reply
    Kemeny, N
    Huang, Y
    Fong, Y
    NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (20): : 1526 - 1527
  • [46] The efficacy and safety of hepatic arterial infusion of oxaliplatin plus intravenous irinotecan, leucovorin and fluorouracil in colorectal cancer with inoperable hepatic metastasis
    Volovat, Simona R.
    Volovat, Constantin
    Negru, Serban M.
    Danciu, Mihai
    Scripcariu, Viorel
    JOURNAL OF CHEMOTHERAPY, 2016, 28 (03) : 235 - 241
  • [47] A systematic review on chronic oxaliplatin-induced peripheral neuropathy and the relation with oxaliplatin administration
    Beijers, A. J. M.
    Mols, F.
    Vreugdenhil, G.
    SUPPORTIVE CARE IN CANCER, 2014, 22 (07) : 1999 - 2007
  • [48] Calcium and magnesium infusions for prevention of oxaliplatin-induced peripheral neuropathy
    Bupathi, M.
    Mahmud, G.
    Kovar, J.
    Wang, E.
    O'Brien, T. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [49] Analgesic Effect of Melittin on Oxaliplatin-Induced Peripheral Neuropathy in Rats
    Choi, Seunghwan
    Chae, Hyeon Kyeong
    Heo, Ho
    Hahm, Dae-Hyun
    Kim, Woojin
    Kim, Sun Kwang
    TOXINS, 2019, 11 (07)
  • [50] Corneal confocal microscopy in patients with oxaliplatin-induced peripheral neuropathy
    Campagnolo, Marta
    Lazzarini, Daniela
    Fregona, Iva
    Cacciavillani, Mario
    Bergamo, Francesca
    Parrozzani, Raffaele
    Midena, Edoardo
    Briani, Chiara
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2013, 18 (03) : 269 - 271